Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial

OBJECTIVES: Riociguat is approved for pulmonary arterial hypertension and has antiproliferative, anti-inflammatory and antifibrotic effects in animal models of tissue fibrosis. We evaluated the efficacy and safety of riociguat in patients with early diffuse cutaneous systemic sclerosis (dcSSc) at hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanna, Dinesh, Allanore, Yannick, Denton, Christopher P, Kuwana, Masataka, Matucci-Cerinic, Marco, Pope, Janet E, Atsumi, Tatsuya, Bečvář, Radim, Czirják, László, Hachulla, Eric, Ishii, Tomonori, Ishikawa, Osamu, Johnson, Sindhu R, De Langhe, Ellen, Stagnaro, Chiara, Riccieri, Valeria, Schiopu, Elena, Silver, Richard M, Smith, Vanessa, Steen, Virginia, Stevens, Wendy, Szücs, Gabriella, Truchetet, Marie-Elise, Wosnitza, Melanie, Laapas, Kaisa, de Oliveira Pena, Janethe, Yao, Zhen, Kramer, Frank, Distler, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213318/
https://www.ncbi.nlm.nih.gov/pubmed/32299845
http://dx.doi.org/10.1136/annrheumdis-2019-216823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213318/
https://www.ncbi.nlm.nih.gov/pubmed/32299845
http://dx.doi.org/10.1136/annrheumdis-2019-216823

Ejemplares similares